Matthew Pincus

Dr. Matthew Pincus

SUNY Downstate Medical Center Brooklyn, NY, United States

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1996 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
VAVictor Adler
Victor Adler
MPMatthew Pincus
Matthew Pincus
SPScott Posner
Scott Posner
PUPramod Upadhyaya
Pramod Upadhyaya
KEKaram El-Bayoumy
Karam El-Bayoumy
ZRZe'Ev Ronai
Ze'Ev Ronai
Activation of Jun-N-kinases (JNK) is stimulated by diverse agents including UV-irradiation, heat shock, tumor necrosis factor and osmotic shock. In the present study we have elucidated the effect of the organoselenium chemopreven-tive agent l, 4-phenylenebis(methylene)selenocyanate (p-XSC), on UV-mediated JNK activation. Using mouse fibroblasts as a model cell system we found that low concentrations (1–10 μM range) of p-XSC did not affect JNK activity, yet were capable of potentiating JNK activity when administered prior to UV-irradiation. While higher doses of p-XSC have minimal effect on JNK activation, when combined with UV, there is a dose-dependent decrease in JNK activation. Similar to its effects on JNK, p-XSC is a potent inducer of src-related tyrosine kinases.p-XSC mediated changes in JNK activation correlate with its ability to potentiate the association of JNK with p21ras, in a manner similar to that we have previously observed with GTP or sodium vanadate. That p-XSC can modulate JNK activities points to a possible mechanism by which it contributes to the cell's ability to cope with stress.

20 April 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ESEhsan Sarafraz-Yazdi
Ehsan Sarafraz-Yazdi
SMStephen Mumin
Stephen Mumin
DCDiana Cheung
Diana Cheung
DFDaniel Fridman
Daniel Fridman
BLBrian Lin
Brian Lin
JMJosef Michl
Josef Michl
PNC-27, a 32-residue peptide that contains an HDM-2 binding domain and a cell-penetrating peptide (CPP) leader sequence kills cancer, but not normal, cells by binding to HDM-2 associated with the plasma membrane and induces the formation of pores causing tumor cell lysis and necrosis. Conformational energy calculations on the structure of PNC-27 bound to HDM-2 suggest that 1:1 complexes form between PNC-27 and HDM-2 with the leader sequence pointing away from the complex. Immuno-scanning electron microscopy was carried out with cancer cells treated with PNC-27 and decorated with an anti-PNC-27 antibody coupled to 6 nm gold particles and an anti-HDM-2 antibody linked to 15 nm gold particles. We found multiple 6 nm- and 15 nm-labeled gold particles in approximately 1:1 ratios in layered ring-shaped structures in the pores near the cell surface suggesting that these complexes are important to the pore structure. No pores formed in the control, PNC-27-treated untransformed fibroblasts. Based on the theoretical and immuno-EM studies, we propose that the pores are lined by PNC-27 bound to HDM-2 at the membrane surface with the PNC-27 leader sequence lining the pores or by PNC-27 bound to HDM-2.

12 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAnna Miller
Anna Miller
DDDavid Diaz
David Diaz
BLBo Lin
Bo Lin
PKPatryk K. Krzesaj
Patryk K. Krzesaj
SUSarah Ustoyev
Sarah Ustoyev
RFRichard Feinman
Richard Feinman
The ketone bodies, sodium and lithium salts of acetoacetate (AcAc) and sodium 3-hydroxybutyrate (3-HB; commonly called beta-hydroxybutyrate) have been found to inhibit the proliferation of cancer cells. Previous studies have suggested that lithium itself may be an inhibiting agent but may be additive or synergistic with the effect of AcAc. We previously found that sodium acetoacetate (NaAcAc) inhibits the growth of human colon cancer cell line SW480. We report here similar results for several other cancer cell lines including ovarian, cervical and breast cancers. We found that NaAcAc does not kill cancer cells but rather blocks their proliferation. Similar inhibition of growth was seen in the effect of lithium ion alone (as LiCl). The effect of LiAcAc appears to be due to the combined effects of acetoacetate and the lithium ion. The ketone bodies, when given together with chemotherapeutic agents, rapamycin, methotrexate and the new peptide anti-cancer agent, PNC-27, substantially lowers their IC50 values for cancer cell, killing suggesting that ketone bodies and ketogenic diets may be powerful adjunct agents in treating human cancers.

22 August 2018
Verified
Book Chapter
Open access
PDF file
AMAmir Momeni-Boroujeni
Amir Momeni-Boroujeni
MPMatthew Pincus
Matthew Pincus
Measurements in laboratory medicine have a degree of uncertainty; this uncertainty is often called “error” and refers to imprecisions and inaccuracies in measurement. This measurement error refers to the difference between the true value of the measured sample and the measured value. One of the types of error is systematic error, also called bias, because these errors errors are reproducible and skew the results consistently in the same direction. A common approach to identify systematic error is to use control samples with a method comparison approach. An alternative is use of statistical methods that analyze actual patient values either as an “Average of Normals” or a “Moving Patient Averages.” Fundamental questions should be decided before a quality control method is used: how are weights assigned to the results? Is preference given to more recent samples or to the older samples? How sensitive should the model be? In this chapter, we will expand the fundamental notion of systematic error and explain why it is difficult to identify and measure and current statistical methods that are used to detect systematic error or bias.

1 December 2016 in Clinics In Laboratory Medicine
Verified
Journal Article
Closed access
MBMartin H. Bluth
Martin H. Bluth
MPMatthew Pincus
Matthew Pincus

8 January 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
ATAnusha Thadi
Anusha Thadi
WMWilliam F. Morano
William F. Morano
MKMarian Khalili
Marian Khalili
BBBlake D. Babcock
Blake D. Babcock
MSMohammad F. Shaikh
Mohammad F. Shaikh
WBWilbur Bowne
Wilbur Bowne
Background/Aim: We have tested whether the anticancer peptide, PNC-27, that kills cancer cells but not normal cells by binding to cancer cell membrane HDM-2 forming pores, kills CD44+ colon cancer stem cells. Materials and Methods: Flow cytometry determined the CD44 and HDM-2 expression on six-colon cancer cell lines and one normal cell line (CCD-18Co). MTT, LDH release, annexin V binding and caspase 3 assays were used to assess PNC-27-induced cell death. Bioluminescence imaging measured PNC-27 effects on in vivo tumor growth. Results: High percentages of cells in all six tumor lines expressed CD44. PNC-27 co-localized with membrane HDM-2 only in the cancer cells and caused total cell death (tumor cell necrosis, high LDH release, negative annexin V and caspase 3). In vivo, PNC-27 caused necrosis of tumor nodules but not of normal tissue. Conclusion: PNC-27 selectively kills colon cancer stem cells by binding of this peptide to membrane H/MDM-2.